BioSpace News Archive

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from the ongoing study of SRP-9003 (rAAVrh74.MHCK7.hSGCB), the Company’s investigational gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E).

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced two-year follow up results from four Duchenne muscular dystrophy (DMD) clinical trial participants who received SRP-9001 (AAVrh74.MHCK7.micro-dystrophin).

Hyprevention has raised new financing to support the V-STRUT© Vertebral Implant product. The financing will be used to execute the commercialization plans for the US spinal fracture market

Imvaq Therapeutics Corp., an innovative cancer immunotherapy company founded by world-leading researchers at Memorial Sloan Kettering Cancer Center (MSK), announced the closing of its $15 million Series B financing.

Castellum, Inc. (OTC: ONOV) announces that it has signed an LOI to acquire a U.S. based government contracting company (the “Company”).

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines.

The Chartis Group, a leading provider of comprehensive advisory services and analytics to the healthcare industry, is pleased to announce the appointment of Dr. Roger Ray as its Chief Physician Executive.

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology,8 announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe.

HandsFree Health™, provider of WellBe®, a secure, HIPAA compliant, voice-enabled virtual health assistant platform, today announced a medical alert system that integrates 24/7 emergency monitoring with the popular voice assistant, WellBe.